Merck's Potential Buyout Of Seagen Expected Within Next Few Weeks: Report

  • Merck & Co Inc MRK is in advanced talks to acquire Seagen Inc SGEN, and an agreement on a purchase is expected in the next few weeks, Wall Street Journal reported citing people familiar with the matter.
  • The potential deal could be worth roughly $40 billion or more.
  • Related: Merck/Seagen Potential Deal Talks Pick Up Speed.
  • The report added that the companies are discussing a price for Seagen above $200 a share.
  • There is still no guarantee that the companies will reach an agreement on a takeover deal.
  • The transaction can help offset the lower Merck sales when its flagship product Keytruda loses patent protection. 
  • According to Cowen estimates, Keytruda could approach 40% of Merck’s sales in 2027.
  • Also Read: This Analyst Believes Seagen Is Evaluating Strategic Alternatives.
  • Any proposed deal is expected to draw a close look from antitrust officials, with Cowen analysts recently predicting “a high likelihood” of litigation from the Justice Department or the Federal Trade Commission.
  • Price Action: SGEN shares are up 4.35% at $182.75 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapM&ANewsHealth CareRumorsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!